Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) unit Shandong Zibo Xincat Pharmaceutical recently received a drug registration certificate approved by China's National Medical Products Administration for its febuxostat tablets, a Monday bourse filing said.
Febuxostat is suitable for the long-term treatment of hyperuricemia in gout patients.
Hong Kong-listed shares of the pharmaceutical company closed over 1% lower on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments